SEC Tracker
Get the app

Verastem VSTM

Verastem raises $234.7M via stock and warrants

Form
8-K
Filed
Importance
Routine
  1. Issued 30,937,500 shares of common stock at $8.00 each
  2. Sold pre-funded warrants to purchase 312,503 shares at $7.9999 each
  3. Expected net proceeds of $234.7M after fees and expenses
  4. Closing expected on Oct 15, 2026

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Verastem files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Corvus Pharmaceuticals CRVS public float $252M, Jun 30, 2025
  2. DBV Technologies DBVT public float $251M, Jun 30, 2025
  3. Atea Pharmaceuticals AVIR public float $263M, Jun 30, 2025
  4. Annexon ANNX public float $244M, Jun 30, 2025
  5. Vanda Pharmaceuticals VNDA public float $269M, Jun 30, 2025